SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Roche Pharma India expands partnership with Cipla

18 Jun 2020 Evaluate
Roche Pharma India has expanded its partnership with domestic pharma major Cipla to further improve access to its key oncology medicines in India. Roche Pharma India has signed a distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1331.10 -3.75 (-0.28%)
05-May-2026 15:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1816.50
Dr. Reddys Lab 1271.70
Cipla 1331.10
Zydus Lifesciences 909.00
Lupin 2344.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×